TandonPDelisleATopalJEGarcia-TsaoG.High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol. 2012;10:1291-1298.
2.
DuPontHLWolfRAIsraelRJPimentelM.Antimicrobial susceptibility of Staphylococcus isolates from the skin of patients with diarrhea-predominant irritable bowel syndrome treated with repeat courses of rifaximin. Antimicrob Agents Chemother. 2017;61:e02165-e02116.
3.
ScarpignatoCPelosiniI.Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73(suppl 1):13-27.
4.
LewisPOKhanIPatelP.Rifampin-resistant Staphylococcus aureus bacteremia in a patient on chronic rifaximin. Ann Pharmacother. 2017;51:617-618.
5.
DebbiaEAMaioliERovetaSMarcheseA.Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother. 2008;20:186-194.
